Mangalam Drugs And Organics Ltd vs Piramal Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Mangalam Drugs and Organics Ltd is ₹ 30.69 as of 08 May 15:30 . The P/E Ratio of Mangalam Drugs and Organics Ltd changed from 17.5 on March 2025 to 0 on March 2023 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Mangalam Drugs and Organics Ltd changed from ₹ 146.65 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 17052 crore on March 2024 to ₹ 8165 crore on March 2023 . This represents a CAGR of -13.69% over 5 years The revenue of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 58.6 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The ebitda of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -1.32 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years .

About Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Limited was initially incorporated as 'Advent Pharma Private Limited' on April 18, 1972.
On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited.
Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001.
The company was established to set up a plant for manufacture of organic and inorganic chemicals. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

FAQs for the comparison of Mangalam Drugs and Organics Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Mangalam Drugs and Organics Ltd or Piramal Pharma Ltd?

Market cap of Mangalam Drugs and Organics Ltd is 48 Cr while Market cap of Piramal Pharma Ltd is 23,893 Cr

What are the key factors driving the stock performance of Mangalam Drugs and Organics Ltd and Piramal Pharma Ltd?

The stock performance of Mangalam Drugs and Organics Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mangalam Drugs and Organics Ltd and Piramal Pharma Ltd?

As of May 8, 2026, the Mangalam Drugs and Organics Ltd stock price is INR ₹30.69. On the other hand, Piramal Pharma Ltd stock price is INR ₹179.75.

How do dividend payouts of Mangalam Drugs and Organics Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Mangalam Drugs and Organics Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.